10-K 0000310764-26-000010 (2026-02-11) vs 10-K 0000310764-25-000023 (2025-02-12)
| Section | Compared text | Words now | Changed |
| Risk Factors | Item 1A | 91 |
not compared |
| MD&A | Item 7 | 1,029 |
85.5% |
| Legal Proceedings | Item 3, via Note 7 – CONTINGENCIES AND COMMITMENTS | 61 |
not compared |
| Accounting Policies | Item 8, Note 1 – SIGNIFICANT ACCOUNTING POLICIES | 39 |
not compared |
The redline: what was cut and what was added
In each section, the paragraph that changed most, marked against last year's 10-K:
cut words struck through, new words highlighted and underlined.
MD&A 90 words changed in this paragraph; it is 52% similar to last year's version.
Operating Income Percent Net Sales MedSurg and Orthopaedics Neurotechnology Orthopaedics 2022 26.0% 29.1% Sales pricing 70 bps (30) bps Volume 100 bps 80 bps Manufacturing and supply chain costs 90 bps (220) bps Research, development and engineering expenses 50 bps 20 bps Selling, general and administrative expenses (60) bps (40) bps 2023 28.5% 27.2% Sales pricing 70 bps 0 bps Volume 40 bps 70 bps Manufacturing and supply chain costs (40) bps (20) bps Research, development and engineering expenses 0 bps 10 bps engineering expenses Selling, general and administrative expenses 40 bps 70 bps expenses 2024 29.6% 28.5% Sales pricing 30 bps 0 bps Volume 90 bps 30 bps Manufacturing and supply chain costs 80 bps (90) bps Research, development and (30) bps 50 bps engineering expenses Selling, general and administrative (140) bps 140 bps expenses 2025 29.9% 29.8%
Source: Item 7, 10-K 0000310764-26-000010 vs Item 7, 10-K 0000310764-25-000023
Every change, by type
Sentences and paragraphs of SYK's Risk Factors and MD&A, 10-K 2026-02-11 against 10-K 2025-02-12.
Each links to the text at sec.gov.
Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier
(may, could, will, not, significant, material…). A year or date rolling forward is not counted.
The full word list
adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would
RemovedRisk Factors
This report contains statements that are not historical facts and are considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current projections about operations, industry conditions, financial condition and liquidity. Words that identify forward-looking statements include, without limitation, words such as “may,” “could,” “will,” “should,” “possible,” “plan,” “predict,” “forecast,” “potential,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “believe,” “may impact,” “on track,” “goal,” “strategy” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, an acquisition or our businesses. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Those statements are not guarantees and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results could differ materially and adversely from these forward-looking statements, historical experience or our present expectations. Some important factors that could cause our actual results to differ from our expectations in any forward-looking statements include:
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedRisk Factors
•weakening of economic conditions, or the anticipation thereof, that could adversely affect the level of demand for our or Inari Medical, Inc.’s (“Inari”) products;
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedRisk Factors
•geopolitical risks, including from international conflicts, which could, among other things, lead to increased market volatility;
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedRisk Factors
•pricing pressures generally, including cost-containment measures that have adversely affected and could in the future adversely affect the price of or demand for our or Inari’s products;
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedRisk Factors
•unanticipated issues arising in connection with clinical studies and otherwise that affect approval of new products, including Inari products, by the FDA and foreign regulatory agencies;
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedRisk Factors
•breaches, failures or other disruptions of our or our vendors’ or customers’ information technology systems or products, including by cyber-attack, data leakage, unauthorized access or theft;
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedRisk Factors
•the ultimate total cost with respect to recall-related and other regulatory and quality matters;
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedRisk Factors
•the impact of legislation to reform the healthcare system in the United States or other countries;
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedRisk Factors
•our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes, including our acquisition of Inari;
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedRisk Factors
•potential negative impacts resulting from climate change or other environmental, social and governance and sustainability related matters;
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedRisk Factors
•the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties;
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedRisk Factors
•uncertainties as to the timing of the tender offer for shares of Inari common stock and the subsequent merger with Inari;
Read it in 10-K 2025-02-12 at sec.gov ↗
AddedMD&A
2023 Gross Selling, Research, Operating Other Income Net Effective Diluted Profit General & Development & Income Income Taxes Earnings Tax Rate EPS Administrative Engineering (Expense), Expenses Expenses Net Reported $13,058 $7,111 $1,388 $3,888 $(215) $508 $3,165 13.8% $8.25 Acquisition and integration-related costs: Inventory stepped-up to fair value — — — — — — — — — Other acquisition and integration-related (a) — (20) — 20 — (25) 45 (0.8) 0.12 Amortization of purchased intangible assets — — — 635 — 132 503 1.2 1.31 Structural optimization and other special charges (b) 39 (130) (1) 170 — 38 132 0.4 0.34 Goodwill and other impairments (c) — — — 36 — 9 27 0.1 0.08 Medical device regulations (d) 2 — (94) 96 — 22 74 0.2 0.19 Recall-related matters (e) — (18) — 18 — 4 14 — 0.04 Regulatory and legal matters (f) — (92) — 92 — 29 63 0.4 0.16 Tax matters (g) — — — — (8) (51) 43 (1.2) 0.11 Adjusted $13,099 $6,851 $1,293 $4,955 $(223) $666 $4,066 14.1% $10.60
Read it in 10-K 2026-02-11 at sec.gov ↗
AddedMD&A
Change in selected assumption Percentage Impairment decline in fair charge value 100 bps increase in discount rate 14% $198 100 bps decrease in long-term revenue growth 8 — 100 bps decrease in long-term operating margin 2 —
Read it in 10-K 2026-02-11 at sec.gov ↗
RemovedMD&A
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. Our goal is to achieve sales growth at the high-end of the medical technology (MedTech) industry and maintain our long-term capital allocation strategy that prioritizes: (1) Acquisitions, (2) Dividends and (3) Share repurchases.
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedMD&A
In 2024 we achieved reported net sales growth of 10.2%. Excluding the impact of acquisitions and divestitures, sales grew 10.2% in constant currency. We reported net earnings of $2,993 and net earnings per diluted share of $7.76. Excluding the impact of certain items, we achieved adjusted net earnings(1) of $4,700 and adjusted net earnings per diluted share(1) of $12.19 representing growth of 15.0%.
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedMD&A
We continued our capital allocation strategy by investing $1,628 in acquisitions and paying $1,219 in dividends to our shareholders.
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedMD&A
In 2024 we completed various acquisitions for total consideration of $1,628 in upfront payments, net of cash acquired, as well as $400 of contingent consideration if certain commercial or clinical milestones are achieved. Refer to Note 6 to our Consolidated Financial Statements for further information.
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedMD&A
In May 2024 we repaid the outstanding $600 principal amount of the 3.375% senior unsecured notes due May 15, 2024. In September 2024 we issued $750 of 4.250% senior unsecured notes due September 11, 2029, €800 of 3.375% senior unsecured notes due September 11, 2032, $750 of 4.625% senior unsecured notes due September 11, 2034 and €600 of 3.625% senior unsecured notes due September 11, 2036. In November 2024 we repaid the outstanding €500 of floating rate senior notes and in December 2024 we repaid €850 of 0.250% senior unsecured notes.
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedMD&A
Note: In the fourth quarter 2024 we reorganized our Spine business to align with certain updates to our internal reporting structure. The spine enabling technologies portfolio (Enabling Technologies) was reclassified to Other Orthopaedics, the interventional spine portfolio was reclassified to Neuro Cranial and the remaining Spine business was renamed to Spinal Implants. Neuro Cranial includes sales related to interventional spine of $413, $327 and $282 for 2024, 2023 and 2022. Other Orthopaedics includes sales related to Enabling Technologies of $152, $149 and $131 for 2024, 2023 and 2022. In the first quarter 2024 a product line previously included in Instruments has been reclassified to Endoscopy to align with a change in our internal reporting structure. We have reflected these changes in all historical periods presented.
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedMD&A
Consolidated net sales in 2024 increased 10.2% as reported and 10.7% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.5%. Excluding the 0.5% impact of acquisitions and divestitures, net sales in constant currency increased by 9.1% from increased unit volume and 1.1% due to higher prices. The unit volume increase was primarily due to higher shipments across all businesses.
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedMD&A
Consolidated net sales in 2023 increased 11.1% as reported and 11.6% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.5%. Excluding the 0.1% impact of acquisitions and divestitures, net sales in constant currency increased by 10.9% from increased unit volume and 0.6% due to higher prices. The unit volume increase was due to higher shipments across all MedSurg and Neurotechnology businesses and most Orthopaedics businesses.
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedMD&A
MedSurg and Neurotechnology net sales in 2024 increased 11.1% as reported and 11.6% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.5%. Excluding the 0.4% impact of acquisitions and divestitures, net sales in constant currency increased by 9.5% from increased unit volume and 1.7% due to higher prices. The unit volume increase was due to higher shipments across all MedSurg and Neurotechnology businesses.
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedMD&A
MedSurg and Neurotechnology net sales in 2023 increased 11.7% as reported and 12.2% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.5%. Excluding the 0.3% impact of acquisitions and divestitures, net sales in constant currency increased by 10.2% from increased unit volume and 1.7% due to higher prices. The unit volume increase was due to higher shipments across all MedSurg and Neurotechnology businesses.
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedMD&A
Orthopaedics net sales in 2024 increased 8.9% as reported and 9.4% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.5%. Excluding the 0.7% impact of acquisitions and divestitures, net sales in constant currency increased by 8.7% from increased unit volume. The unit volume increase was due to higher shipments across all Orthopaedics businesses.
Read it in 10-K 2025-02-12 at sec.gov ↗
RemovedMD&A
Orthopaedics net sales in 2023 increased 10.3% as reported and 10.9% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.6%. Excluding the 0.1% impact of acquisitions and divestitures, net sales in constant currency increased by 11.9% from increased unit volume partially offset by 1.1% due to lower prices. The unit volume increase was due to higher shipments across most Orthopaedics businesses.
Read it in 10-K 2025-02-12 at sec.gov ↗
RewordedMD&A
Operating Income Percent Net Sales MedSurg and Orthopaedics Neurotechnology Orthopaedics 2022 26.0% 29.1% Sales pricing 70 bps (30) bps Volume 100 bps 80 bps Manufacturing and supply chain costs 90 bps (220) bps Research, development and engineering expenses 50 bps 20 bps Selling, general and administrative expenses (60) bps (40) bps 2023 28.5% 27.2% Sales pricing 70 bps 0 bps Volume 40 bps 70 bps Manufacturing and supply chain costs (40) bps (20) bps Research, development and engineering expenses 0 bps 10 bps engineering expenses Selling, general and administrative expenses 40 bps 70 bps expenses 2024 29.6% 28.5% Sales pricing 30 bps 0 bps Volume 90 bps 30 bps Manufacturing and supply chain costs 80 bps (90) bps Research, development and (30) bps 50 bps engineering expenses Selling, general and administrative (140) bps 140 bps expenses 2025 29.9% 29.8%
Read it in 10-K 2026-02-11 at sec.gov ↗
RewordedMD&A
Gross Profit Percent Net Sales 2022 62.8% Sales pricing 20 bps Volume and mix 100 bps Manufacturing and supply chain costs (40) bps Inventory stepped up to fair value 10 bps 2023 63.7% Sales pricing 40 bps Volume and mix 60 bps Manufacturing and supply chain costs (40) bps Inventory stepped up to fair value (20) bps Structural optimization and other special charges (20) bps 2024 63.9% Sales pricing 10 bps Volume and mix 70 bps Manufacturing and supply chain costs 0 bps Inventory stepped up to fair value (60) bps Structural optimization and other special charges (10) bps 2025 64.0%
Read it in 10-K 2026-02-11 at sec.gov ↗
RewordedMD&A
(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union.
Read it in 10-K 2026-02-11 at sec.gov ↗
RewordedMD&A
(1) Refer (1)Refer to "Non-GAAP Financial Measures" for a discussion of non-GAAP financial measures used in this report and a reconciliation to the most directly comparable GAAP financial measure.
Read it in 10-K 2026-02-11 at sec.gov ↗
RewordedMD&A
(e) (f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain recall-related matters.
Read it in 10-K 2026-02-11 at sec.gov ↗
Quiet changesMD&A
(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain recall-related matters.
Read it in 10-K 2026-02-11 at sec.gov ↗